PL3093022T3 - Inhibitory gata-3 do zastosowania do leczenia astmy powodowanej przez th2 - Google Patents
Inhibitory gata-3 do zastosowania do leczenia astmy powodowanej przez th2Info
- Publication number
- PL3093022T3 PL3093022T3 PL15001472T PL15001472T PL3093022T3 PL 3093022 T3 PL3093022 T3 PL 3093022T3 PL 15001472 T PL15001472 T PL 15001472T PL 15001472 T PL15001472 T PL 15001472T PL 3093022 T3 PL3093022 T3 PL 3093022T3
- Authority
- PL
- Poland
- Prior art keywords
- gata
- inhibitors
- treatment
- driven asthma
- asthma
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/127—DNAzymes
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15001472.8A EP3093022B1 (en) | 2015-05-15 | 2015-05-15 | Gata-3 inhibitors for use in the treatment of th2-driven asthma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3093022T3 true PL3093022T3 (pl) | 2020-02-28 |
Family
ID=53274335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15001472T PL3093022T3 (pl) | 2015-05-15 | 2015-05-15 | Inhibitory gata-3 do zastosowania do leczenia astmy powodowanej przez th2 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10487325B2 (pl) |
| EP (1) | EP3093022B1 (pl) |
| JP (1) | JP2018515611A (pl) |
| KR (1) | KR20180004816A (pl) |
| CN (2) | CN107771082A (pl) |
| AU (1) | AU2016264772B2 (pl) |
| BR (1) | BR112017024394A2 (pl) |
| CA (1) | CA2985858C (pl) |
| DK (1) | DK3093022T3 (pl) |
| ES (1) | ES2753436T3 (pl) |
| HU (1) | HUE046190T2 (pl) |
| PL (1) | PL3093022T3 (pl) |
| PT (1) | PT3093022T (pl) |
| RU (1) | RU2720988C2 (pl) |
| SI (1) | SI3093022T1 (pl) |
| WO (1) | WO2016184556A1 (pl) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10905710B2 (en) * | 2016-05-24 | 2021-02-02 | Emory University | Particles with RNA cleaving nucleobase polymers and uses for managing inflammatory disorders |
| EP3501607A1 (de) * | 2017-12-22 | 2019-06-26 | Sterna Biologicals GmbH & Co. KG | Zusammensetzung zur behandlung eines an einer mit chronischen entzündungen einhergehenden atemwegserkrankung leidenden patienten sowie herstellungsverfahren und verwendung der zusammensetzung |
| EP3603617A1 (de) * | 2018-07-30 | 2020-02-05 | Sterna Biologicals GmbH & Co. KG | Aerosolerzeugungseinrichtung zur inhalativen verabreichung einer antisense-molekül-haltigen zusammensetzung |
| EP3805242A1 (en) * | 2019-10-07 | 2021-04-14 | Sterna Biologicals GmbH & Co. KG | Method for the production of a catalytically active dna molecule having improved activity and its use in a method of treating asthma |
| CN112023062A (zh) * | 2020-09-18 | 2020-12-04 | 北京基因安科技有限公司 | 一个用可溶性IgE受体抑制过敏反应的方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2340322A1 (en) | 1998-08-13 | 2000-02-24 | Johnson & Johnson Research Pty Limited | Dnazymes and methods for treating restenosis |
| AUPP810399A0 (en) | 1999-01-11 | 1999-02-04 | Unisearch Limited | Catalytic molecules |
| JP2002537792A (ja) | 1999-03-05 | 2002-11-12 | エピジェネシス ファーマシューティカルズ，アイエヌシー | 標的および経路をバリデート／インバリデートする方法 |
| AUPQ201499A0 (en) | 1999-08-04 | 1999-08-26 | Unisearch Limited | Treatment of inflammatory and malignant diseases |
| WO2002068637A2 (en) | 2000-10-20 | 2002-09-06 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid-based treatment of diseases or conditions related to west nile virus infection |
| DE10346487A1 (de) * | 2003-10-02 | 2005-05-12 | Transmit Technologietransfer | Verfahren zur Herstellung eines Zell- und/oder Gewebe- und/oder Krankheitsphasen-spezifischen Arzneimittels |
| TWI322690B (en) * | 2006-05-11 | 2010-04-01 | Flysun Dev Co Ltd | Short interference ribonucleic acids for treating allergic dieases |
| DE102010007562A1 (de) * | 2010-02-10 | 2011-08-11 | sterna biologicals GmbH & Co KG, 35043 | Dermatologische, pharmazeutische Zusammensetzung geeignet für Oligonukleotide |
| EP2708898A1 (de) | 2012-09-14 | 2014-03-19 | Sterna Biologicals GmbH & Co. Kg | Verfahren zur Diagnose eines molekularen Phänotyps eines an einer mit chronischen Entzündungen einhergehenden Erkrankung leidenden Patienten |
-
2015
- 2015-05-15 SI SI201530949T patent/SI3093022T1/sl unknown
- 2015-05-15 ES ES15001472T patent/ES2753436T3/es active Active
- 2015-05-15 EP EP15001472.8A patent/EP3093022B1/en active Active
- 2015-05-15 PT PT150014728T patent/PT3093022T/pt unknown
- 2015-05-15 HU HUE15001472A patent/HUE046190T2/hu unknown
- 2015-05-15 PL PL15001472T patent/PL3093022T3/pl unknown
- 2015-05-15 DK DK15001472T patent/DK3093022T3/da active
-
2016
- 2016-05-12 JP JP2018511332A patent/JP2018515611A/ja active Pending
- 2016-05-12 CN CN201680027457.9A patent/CN107771082A/zh active Pending
- 2016-05-12 KR KR1020177036013A patent/KR20180004816A/ko active Search and Examination
- 2016-05-12 RU RU2017143014A patent/RU2720988C2/ru active
- 2016-05-12 CA CA2985858A patent/CA2985858C/en active Active
- 2016-05-12 US US15/574,345 patent/US10487325B2/en active Active
- 2016-05-12 BR BR112017024394-6A patent/BR112017024394A2/pt not_active Application Discontinuation
- 2016-05-12 AU AU2016264772A patent/AU2016264772B2/en active Active
- 2016-05-12 CN CN202210796084.9A patent/CN115137827A/zh active Pending
- 2016-05-12 WO PCT/EP2016/000782 patent/WO2016184556A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| RU2017143014A (ru) | 2019-06-17 |
| CA2985858A1 (en) | 2016-11-24 |
| DK3093022T3 (da) | 2019-11-04 |
| RU2017143014A3 (pl) | 2019-10-25 |
| AU2016264772A1 (en) | 2017-11-16 |
| EP3093022A1 (en) | 2016-11-16 |
| US20190062737A1 (en) | 2019-02-28 |
| CN107771082A (zh) | 2018-03-06 |
| EP3093022B1 (en) | 2019-08-07 |
| SI3093022T1 (sl) | 2019-12-31 |
| CN115137827A (zh) | 2022-10-04 |
| BR112017024394A2 (pt) | 2018-07-24 |
| AU2016264772B2 (en) | 2021-09-09 |
| WO2016184556A1 (en) | 2016-11-24 |
| JP2018515611A (ja) | 2018-06-14 |
| HUE046190T2 (hu) | 2020-02-28 |
| CA2985858C (en) | 2023-10-10 |
| US10487325B2 (en) | 2019-11-26 |
| ES2753436T3 (es) | 2020-04-08 |
| PT3093022T (pt) | 2019-11-11 |
| RU2720988C2 (ru) | 2020-05-15 |
| KR20180004816A (ko) | 2018-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1259232A1 (zh) | Menin-mll的取代抑制劑及其使用方法 | |
| HK1249524A1 (zh) | 用於治療血載癌症的免疫檢查點抑制劑 | |
| HK1252693A1 (zh) | Egfr抑制劑及其使用方法 | |
| IL261721A (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
| IL267291A (en) | Actonucleotidase inhibitors and methods of using them | |
| IL259801A (en) | ezh2 inhibitors and methods of using them | |
| HRP20181205T1 (hr) | Glyt1 inhibitori za uporabu u liječenju hematoloških poremećaja | |
| IL267238A (en) | The paranase inhibitors and their use | |
| IL251904A0 (en) | Epilimod for use in the treatment of melanoma | |
| HK1257171A1 (zh) | 間變性淋巴瘤激酶（alk）和絲氨酸富集蛋白激酶 （sppk）的抑制劑及其使用方法 | |
| IL263804A (en) | Wnt inhibitors for use in the treatment of fibrosis | |
| IL255530A (en) | Efflux-pump inhibitors and therapeutic uses thereof | |
| PL3093022T3 (pl) | Inhibitory gata-3 do zastosowania do leczenia astmy powodowanej przez th2 | |
| HK1250028A1 (zh) | 2-苯基-6-咪唑基-吡啶-4-甲酰胺衍生物及其作為eaat3抑制劑的用途 | |
| GB201702160D0 (en) | Inhibitors for use in therapy | |
| HK1250926A1 (zh) | 抑制劑及其應用 | |
| IL251840A0 (en) | Use of femiroplast in the treatment of severe asthma | |
| HK1255029A1 (zh) | 明膠酶抑制劑及其用途 | |
| IL267243A (en) | The paranase inhibitors and their use | |
| HK1217299A1 (zh) | 用於治療急性或慢性肺動脈高血壓的 抑制劑 | |
| GB201509977D0 (en) | Dispensers and methods of use thereof | |
| GB201505975D0 (en) | Inhibitors and their uses | |
| GB201505971D0 (en) | Inhibitors and their uses | |
| ZA201408464B (en) | Composition for the use in treatment of asthma | |
| GB201409466D0 (en) | Urea compounds and their use as enzyme inhibitors |